{{Rsnum
|rsid=4803750
|Chromosome=19
|position=44744370
|Orientation=plus
|GMAF=0.08219
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene=BCL3
|Gene_s=BCL3
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 84.1 | 15.0 | 0.9
| HCB | 82.5 | 17.5 | 0.0
| JPT | 79.6 | 19.5 | 0.9
| YRI | 86.4 | 12.9 | 0.7
| ASW | 78.9 | 19.3 | 1.8
| CHB | 82.5 | 17.5 | 0.0
| CHD | 92.7 | 7.3 | 0.0
| GIH | 66.3 | 29.7 | 4.0
| LWK | 87.3 | 12.7 | 0.0
| MEX | 62.1 | 36.2 | 1.7
| MKK | 76.3 | 23.1 | 0.6
| TSI | 93.1 | 6.9 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4803750
|Name_s=
|Gene_s=BCL3
|Feature=
|Evidence=PubMed ID:19802338
|Annotation=Phenotype: In a GWAS, this SNP was significantly associated with plasma concentrations of LDL-C and apolipoprotein B. Study size: 6382. Study population/ethnicity: Caucasian women. Significance metric(s): LDL-C: p = 3.6 x 10 (-14);ApoB: p = 8.7 x 10(-19). Type of association: CO; GN
|Drugs=
|Drug Classes=
|Diseases=Cardiovascular Diseases
|Curation Level=Curated
|PharmGKB Accession ID=PA165111816
}}

{{PMID|18262040|OA=1
}} LDL-cholesterol concentrations: a genome-wide association study.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4803750
|overall_frequency_n=10
|overall_frequency_d=126
|overall_frequency=0.0793651
|n_genomes=9
|n_genomes_annotated=0
|n_haplomes=9
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23100282
|Title=Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Illumina Human 1M}}